Personalized Management in Chronic Obstructive Pulmonary Disease (COPD)

A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Personalized Therapy in Clinical Medicine".

Deadline for manuscript submissions: 31 January 2027 | Viewed by 1826

Special Issue Editor


E-Mail Website
Guest Editor
Pulmonology Unit, Department of Biomedical, Dental, Morphological and Functional Imaging Sciences (BIOMORF), University of Messina, Via Consolare Valeria, 1, 98124 Messina, Italy
Interests: chronic obstructive pulmonary disease; airway obstruction; pulmonology; allergy
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Chronic obstructive pulmonary disease (COPD) is a complex and heterogeneous disease that is continuously increasing in the adult and elderly population. The diagnosis of COPD is too late in the natural history of the disease, and the presence of numerous comorbidities at the time of diagnosis affects its clinical management. The use of personalized medicine is essential to achieve meaningful clinical outcomes. Current COPD management is still based on predictable and binary outcomes, supported by randomised clinical trials, does not tolerate uncertainty, and is far from personalised management algorithms maximising health benefits concerning symptoms for the individual patient.

The purpose of this Special Issue is to focus on the main aspects of a personalized approach to COPD management. We are soliciting in-depth commentary, original research (including communications), and review articles with a focus on new developments and important advances in the personalized management of COPD. The main aspects of a personalized approach to COPD management could be the role of early diagnosis of the disease, functional phenotyping, comorbidities management with particular regard to the concept of future cardiopulmonary risk, personalized management of exacerbations, and personalized long-term therapy of the disease, including personalized end-of-life management. 

Dr. Paolo Ruggeri
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • COPD
  • lung function
  • comorbidities
  • cardiopulmonary risk
  • exacerbation
  • inhalation therapy
  • early diagnosis
  • phenotyping

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

15 pages, 1530 KB  
Review
Sex and Gender in Chronic Obstructive Pulmonary Disease: Does It Matter?
by Christos Kyriakopoulos, Georgios Hillas, Antonia Assioura, Anastasia Papanikolaou, Vasileios Angelopoulos, Konstantinos Kostikas and Athena Gogali
J. Pers. Med. 2026, 16(3), 152; https://doi.org/10.3390/jpm16030152 - 6 Mar 2026
Viewed by 1267
Abstract
Chronic obstructive pulmonary disease (COPD) is a major contributor to global respiratory morbidity and exhibits substantial sex- and gender-related differences in incidence, phenotype, pathophysiology, and outcomes across the life course. Historically regarded as a predominantly male disease due to higher smoking rates, COPD [...] Read more.
Chronic obstructive pulmonary disease (COPD) is a major contributor to global respiratory morbidity and exhibits substantial sex- and gender-related differences in incidence, phenotype, pathophysiology, and outcomes across the life course. Historically regarded as a predominantly male disease due to higher smoking rates, COPD is now increasingly recognized among women, reflecting changing exposure patterns and enhanced diagnostic attention. Moreover, evidence indicates that women may be more biologically susceptible to the harmful effects of tobacco smoke and often develop COPD at younger ages. Clinical manifestations also differ, with women more frequently reporting dyspnea, anxiety, and depression, whereas men may exhibit more cough and sputum production. Imaging studies suggest that airway-predominant disease is more common in women, while men are more likely to demonstrate emphysema-predominant patterns. Furthermore, women face an increased risk of exacerbation, yet they are more likely to experience underdiagnosis or misdiagnosis. Treatment responses and comorbidity patterns also show sex- and gender-related variations. Despite these differences, most clinical guidelines and therapeutic strategies do not differentiate by sex and gender, highlighting a gap in personalized COPD management. Overall, growing evidence underscores the importance of incorporating sex and gender as biological and sociocultural variables in COPD research, diagnosis, and treatment. Recognizing sex/gender-specific risk profiles, symptom patterns, and disease phenotypes may improve early detection and enable more targeted, effective interventions. This narrative synthesis, derived from a meticulous search in PubMed and the critical selection of 74 articles from the 448 identified originally, integrates evidence from guideline statements, registry studies, mechanistic and preclinical research, imaging and physiology investigations, systematic reviews, and randomized controlled trials that report sex- and gender-disaggregated data. Full article
Show Figures

Figure 1

Back to TopTop